Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Epratuzumab in Active Systemic Lupus Erythematosus
2005-000706-31Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Epratuzumab with Placebo (2 arms). Primary endpoint: Primary efficacy response at 24 weeks. Started Apr 2005; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2005-000706-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000706-31.